<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">poly ADP-ribose polymerase (PARP) inhibitor</span> <span style="margin-left: 1em;">olaparib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (5) progression or deaths (PFS) (5) objective responses (ORR) (5) DOR (4) DCR (2) SAE (any grade) (1) TRAE (grade 3-4) (1) TRAE leading to death (grade 5) (1) TRAE leading to discontinuation (any grade) (1) Pruritus TRAE (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (1) Colitis TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Thyroiditis TRAE (grade 3-4) (1) Fatigue TRAE (grade 3-4) (1) Nausea TRAE (grade 3-4) (1) Anaemia TRAE (grade 3-4) (1) Maculopapular rash TRAE (grade 3-4) (1) Decreased appetite TRAE (grade 3-4) (1) Asthenia TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Pyrexia TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Thrombocytopenia TRAE (grade 3-4) (1) Neutropenia TRAE (grade 3-4) (1) Constipation TRAE (grade 3-4) (1) Leucopenia TRAE (grade 3-4) (1) Cough TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Abdominal pain TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Headache TRAE (grade 3-4) (1) Adrenal insufficiency TRAE (grade 3-4) (1) Diabetes TRAE (grade 3-4) (1) Severe skin reaction TRAE (grade 3-4) (1) Nephritis TRAE (grade 3-4) (1) Myositis TRAE (grade 3-4) (1) Weight decreased TRAE (grade 3-4) (1) Stomatitis TRAE (grade 3-4) (1) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1) Urticaria TRAE (grade 3-4) (1) Acute kidney injury TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Pancytopenia TRAE (grade 3-4) (1) Sepsis TRAE (grade 3-4) (1) Pneumonia TRAE (grade 3-4) (1) Peripheral sensory neuropathy TRAE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 KEYNOTE-119 (all population), 2019 1 OlympiAD, 2017 olaparib vs. pembrolizumab alone
0.93 [0.65; 1.32] 0.93 [0.65;1.32]olaparib vs. pembrolizumab alone
0.93 [0.65; 1.32] olaparib vs. Standard of Care (SoC)
0.90 [0.66; 1.23] 0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC)
0.90 [0.66; 1.23] pembrolizumab alone vs. olaparib
1.08 [0.76; 1.54] 1.08 [0.76;1.54]pembrolizumab alone vs. olaparib
1.08 [0.76; 1.54] pembrolizumab alone vs. Standard of Care (SoC)
0.97 [0.82; 1.15] 0.97 [0.82;1.15]pembrolizumab alone vs. Standard of Care (SoC)
0.97 [0.82; 1.15] Standard of Care (SoC) vs. olaparib
1.11 [0.81; 1.52] 1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib
1.11 [0.81; 1.52] Standard of Care (SoC) vs. pembrolizumab alone
1.03 [0.87; 1.22] 1.03 [0.87;1.22]Standard of Care (SoC) vs. pembrolizumab alone
1.03 [0.87; 1.22] Standard of Care (SoC) pembrolizumab alone olaparib direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) pembrolizumab alone olaparib Standard of Care (SoC) --- 1.03 0.87; 1.221.11 0.81; 1.52pembrolizumab alone 0.97 0.82; 1.15--- 1.08 0.76; 1.54olaparib 0.90 0.66; 1.230.93 0.65; 1.32---
pathologies: 140
- treatments: 483
result logic